BiotechTube

Terlipressin acetate + Serelaxin (RLX030)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Compensated Cirrhosis and Portal Hypertension

Conditions

Compensated Cirrhosis and Portal Hypertension

Trial Timeline

Apr 1, 2013 → Dec 1, 2014

NCT ID
NCT01640964

About Terlipressin acetate + Serelaxin (RLX030)

Terlipressin acetate + Serelaxin (RLX030) is a phase 2 stage product being developed by Novartis for Compensated Cirrhosis and Portal Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01640964. Target conditions include Compensated Cirrhosis and Portal Hypertension.

What happened to similar drugs?

3 of 5 similar drugs in Compensated Cirrhosis and Portal Hypertension were approved

Approved (3) Terminated (1) Active (2)
✅Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
✅telbivudine/LDT600NovartisApproved
✅Telbivudine/LDT600ANovartisApproved
🔄Aliskiren + PlaceboNovartisPhase 3
🔄Albutein 20%GrifolsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01640964Phase 2Completed

Competing Products

9 competing products in Compensated Cirrhosis and Portal Hypertension

See all competitors
ProductCompanyStageHype Score
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
Mesenchymal Stem CellRohto PharmaceuticalPre-clinical
26
Mesenchymal stem cellRohto PharmaceuticalPhase 1/2
32
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
39
telbivudine/LDT600NovartisApproved
43
Aliskiren + PlaceboNovartisPhase 3
40
Telbivudine/LDT600ANovartisApproved
35
BMS-986259Bristol Myers SquibbPhase 2
35
Albutein 20%GrifolsPhase 3
37